Allergy Therapeutics PLC Stock
Your prediction
Allergy Therapeutics PLC Stock
The price for the Allergy Therapeutics PLC stock decreased slightly today. Compared to yesterday there is a change of -€0.001 (-0.530%).
Pros and Cons of Allergy Therapeutics PLC in the next few years
Pros
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Allergy Therapeutics PLC vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allergy Therapeutics PLC | -0.530% | -13.281% | -15.267% | 58.571% | -5.128% | 133.684% | -46.117% |
| Beximco Pharmaceuticals Ltd. GDR | 0.000% | 8.193% | -0.962% | 18.664% | 14.955% | -3.738% | -47.980% |
| Eledon Pharmaceuticals Inc. | -0.570% | 7.407% | 0.000% | -58.962% | 35.938% | -30.400% | -88.917% |
| SELLAS Life Sciences Group Inc | 2.270% | 4.383% | -5.857% | 163.525% | 13.404% | 6.071% | -57.122% |
News
AT&T's Secret Weapon for 2026: Why Fiber Could Drive Double-Digit EPS Growth
Telecom powerhouse AT&T (NYSE: T) is certainly a respectable company and a great dividend payer. But is it a growth stock? Hardly.
Except, for the foreseeable future, it's going to be putting up
AT&T Plans to Return $45 Billion to Shareholders. Is the Stock a Buy for 2026?
AT&T (NYSE: T) cut its dividend by nearly 50% in 2022. That move followed the spinoff of WarnerMedia, undoing what, in hindsight, proved to be a disastrous acquisition. Those two decisions set AT&T
Why AT&T Stock Surged This Week
Shares of AT&T (NYSE: T) jumped more than 10% this past week, according to data from S&P Global Market Intelligence.
The wireless carrier delivered an impressive quarterly financial report and